

Nonsteroidal MRAs in CKD and T2D: Current knowledge and practical insights

WONCA 2023

June 9th 12:45 -13:45h

Brussels

Date of preparation: June 2023

Approval code: MA-M_FIN-ALL-1180-3



Communication objectives

- To provide an overview in the current unmet medical need in the management of T2D and CKD patients with regards to preventing renal and CV risk and highlight the most recent treatment recommendations for the management of these patients
- To discuss the current treatment landscape for patients with T2D and CKD and the role of nsMRAs, specifically finerenone, in the current T2D CKD patient pathway
- To provide an overview of finerenone practical management with regards to initiation, monitoring and potassium management in clinical practice and looking at real world cases
- To highlight and discuss significance of PCPs in early diagnosis for the treatment pathway, what are the barriers to UACR screening in primary care (summary of key feedback from October 2022) and how to collaborate to improve patient outcomes: the CHECK initiative

Programme

Time (CEST)	Title	Speaker
12:45-12:50	Welcome and introduction	Paola Fioretto
12:50-13:05	CKD in T2D – Treatment approaches and unmet needs <ul style="list-style-type: none">• UACR as a clinical marker and diagnostic tool for cardiorenal outcomes• The benefit of early CKD diagnosis for patients with T2D: Albuminuria as a clinical marker• Overview of CKD T2D Guidelines (including KDIGO)	Paola Fioretto
13:05-13:15	Finerenone in the current CKD in T2D therapeutic landscape <ul style="list-style-type: none">• Introduction to finerenone: MoA, differentiation from steroidal MRAs and key insights from FIDELITY• Finerenone as a Pillar of CKD T2D management	Geert Goderis
13:15-13:30	Practical considerations for the management of patients with CKD and T2D <ul style="list-style-type: none">• Treatment initiation, monitoring, potassium management protocols• Through patient cases	Romeo Providoli
13:30-13:45	Discussion panel: The significance of PCPs in early diagnosis for the treatment pathway <ul style="list-style-type: none">• Barriers to UACR screening in primary care (summary of key feedback from October 2022)• Collaborating to improve patient outcomes: the CHECK initiative	All

Date of preparation: June 2023

Approval code: MA-M_FIN-ALL-1180-3